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Abstract
Background: Each year in the UK, ≈3000 children undergo major cardiac surgery requiring cardiopulmonary bypass.
Approximately 40 % of these experience excessive bleeding necessitating red cell transfusion or treatment with other
blood components. A further 40 % receive blood components because of the perception by clinicians that the risk of
bleeding is high. Excessive bleeding and treatment with red cell transfusion or blood components are associated with
post-operative complications such as infection and renal injury and are independently associated with increased
morbidity and mortality.
Abnormalities in blood coagulation are a major cause of excessive bleeding after cardiac surgery in children.
However, the extent of these abnormalities varies between children and their characteristics may change rapidly
during surgery. In adults undergoing cardiac surgery, rapid testing of blood coagulation using techniques such as
thromboelastometry may assist the selection of appropriate blood component treatments. In some sub-groups of
adults, this improves clinical outcomes. Rapid testing of blood coagulation in children undergoing cardiac
surgery has not been evaluated fully.
Methods/Design: The DECISION study is a prospective, single-centre, observational study that aims to assess the
utility of rapid testing of blood coagulation in children undergoing cardiac surgery. This will be achieved by testing blood
samples from 200 children obtained immediately before, and after cardiac surgery. The blood samples will be analysed in
parallel using thromboelastometry and reference laboratory tests of blood coagulation. The primary clinical outcome will
be clinical concern about bleeding, defined as a composite of either excessive blood loss or the use of a pro-haemostatic
treatment outside of standard treatment protocols because of perceived high risk of excessive bleeding. The reference
laboratory test results will be used to describe the patterns of abnormalities in blood coagulation in children and will be
compared to the thromboelastometry test results to determine the diagnostic accuracy of the thromboelastometry tests.
We will estimate how well the reference and thromboelastometry test results predict clinical concern about bleeding.
Discussion: The DECISION study will identify the most useful thromboeastometry tests of blood coagulation for the
prediction of excessive bleeding in children after cardiac surgery and will inform the design of future randomised
controlled trials.
Trial registration: The trail was registered as ISRCTN55439761 on 23rd April 2015.
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Background
Better blood and blood component transfusion is a long-
standing NHS priority that is highly pertinent to cardiac
surgery since the 40,000 cardiac surgery procedures in the
UK each year account for 18 % of all NHS blood compo-
nents used. This statistic includes 3,000 children who
undergo cardiac surgery requiring cardiopulmonary by-
pass (CPB) and who have a 30-day mortality of 4 % and
post-operative morbidity from organ injury or sepsis of
about 25 % [1]. Excessive bleeding occurs in 40 % of chil-
dren after cardiac surgery and is typically treated by trans-
fusion of red cells and other blood components such as
fresh frozen plasma, cryoprecipitate or platelet concen-
trates. However, in current NHS practice, a further 40 %
of children receive blood components empirically at the
end of surgery in an attempt to prevent excessive bleeding
[2]. Decisions to administer blood components are not
standardised and there is marked variation between NHS
centres in the prevalence of excessive bleeding and in
blood component use [2]. Excessive bleeding and transfu-
sion of red cells or other components are independently
associated with increased risk of post-operative morbidity
and mortality arising from adverse events such as sepsis
and kidney, brain and lung injury [1]. Adverse events have
a significant impact on children and their families and
substantially increases healthcare costs.
A major cause of excessive bleeding in children after
cardiac surgery is abnormality in the blood clotting sys-
tem. This is typically complex and multi-factorial and
may be influenced by blood clotting abnormalities that
pre-exist in the child. However, blood clotting is also af-
fected by anaesthetic techniques that are essential for
cardiac surgery to be performed. Therefore, blood clot-
ting abnormalities vary markedly between children and
change within individual children during the course of
surgery [3–5]. Amongst the range of possible blood clot-
ting abnormalities, low platelets and low fibrinogen have
been most commonly observed in small single-centre or
single-diagnosis groups of children and were associated
with excessive bleeding [3–5]. Associations between these
blood clotting abnormalities and excessive bleeding have
not been tested in larger unselected cohorts.
Since different blood clotting abnormalities usually re-
quire different blood components, treatments to prevent
or treat bleeding must be selected quickly and must be
individualised to each patient. In adults undergoing car-
diac surgery, this is currently assisted by rapid testing of
blood clotting using techniques such as thromboelastome-
try (TEM), which is usually performed as a point-of-care
test. TEM may yield diagnostically useful information
about the characteristics and severity of blood clotting ab-
normalities during or after cardiac surgery. TEM test re-
sults are typically incorporated into simple treatment
algorithms to assist selection of the most appropriate
blood component or pharmaceutical treatments to reverse
the blood clotting abnormality. Individualised treatment of
blood clotting abnormalities informed by rapid test results
has been shown to reduce red cell and blood component
use in several clinical trials in adults [6–8] and to improve
clinical outcomes in some patient groups [9].
Although TEM testing of blood clotting is an effective
clinical strategy in adults undergoing cardiac surgery,
the role of TEM testing in children is less clearly de-
fined. In part this is because existing evidence suggests
that the changes in blood clotting that develop in chil-
dren during cardiac surgery are qualitatively different to
those in adults and develop with different kinetics [3–5].
Consequently, diagnostic inferences from the results of
TEM tests in adults cannot necessarily be extended to
children and treatment decisions based on these results
may not be valid. Although TEM tests are now per-
formed after cardiac surgery in about 25 % of children in
NHS hospitals [2], testing is not standardised and treat-
ment decisions guided by TEM results have not been
validated.
The Detection of Coagulopathy in Paediatric Heart
Surgery (DECISION) Study has been developed to better
define the clinical utility of blood clotting testing in chil-
dren undergoing cardiac surgery and to identify areas
for evaluation in future randomised controlled trials. It
is anticipated that improvements in the diagnosis of
blood clotting abnormalities in children will assist selec-
tion of appropriate blood components to prevent or
treat excessive bleeding which may reduce blood compo-




The overall aim of the study is to evaluate whether TEM
testing for blood clotting abnormalities in children be-
fore or after cardiac surgery will improve prediction of
excessive bleeding after cardiac surgery.
This may confer direct clinical and economic benefits
in two ways; 1) test results may improve selection of the
best treatments for children with blood clotting abnor-
malities to prevent or stop excessive bleeding, and, b)
test results may prevent the use of unnecessary treat-
ments in children who do not have blood clotting abnor-
malities and are at low risk of excessive bleeding.
The study objectives are as follows:
1. To describe the prevalence of the different types of
blood clotting abnormality in children before and
after cardiac surgery.
2. To estimate the extent to which the TEM and
reference laboratory test results predict (a) clinical
concern about bleeding after cardiac surgery and (b)
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different types of blood clotting abnormality and
clinical concern about bleeding after cardiac surgery.
3. To estimate the diagnostic accuracy of TEM test
results vs. reference laboratory tests for the different
types of blood clotting abnormality identified (a)
before and (b) after cardiac surgery.
4. To investigate the agreement between the treatment
recommended by the results of the reference tests
and the treatment recommended by the TEM test
results(see Figure 1 for study schema)
Study design
Prospective, single-centre, observational cohort study
(see Figure 1 for study schema).
Study population
Children at the Bristol Royal Hospital for Children at
high or moderate risk of bleeding after cardiac surgery.
Consent
For all potential participants younger than 11 years
old, the parents or guardians gave written consent
after eligibility checking. For potential participants be-
tween 11 and 15 years old, signed assent was obtained
from the participants and written consent from par-
ents or guardians. The participants who were16 years
old gave written consent. The study was conducted
after UK Research Ethics Committee approval (NRES
Fig. 1 Study Schema
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Committee London - City & East 13/LO/0504) in ac-
cordance with the Declaration of Helsinki.
Inclusion criteria
Participants may enter the study if ALL of the following
apply:
1. Cardiac surgery requiring CPB (thereby at high or
moderate bleeding risk)
2. Age ≤16 years old
3. Weight >2.5 Kg
Exclusion criteria
Participants may not enter the study if ANY of the fol-
lowing apply-
1. Emergency cardiac surgery
2. Unable to give informed consent (16 year olds only)
3. In foster care and parents/guardians unavailable to
consent
Study interventions
1. Two 5.25 ml blood samples will be taken from
existing intravascular lines at two time-points:
Sample 1, immediately following anaesthetic
induction.
2. Sample 2, after cessation of CPB, heparin reversal
and other routinely performed interventions that
may influence blood clotting such as cell saver
return but before the start of the return of pump
blood (see below).
The volume of the blood required may, in exceptional
circumstances, be tolerated poorly by participants with
small circulating volumes or critical cardiovascular func-
tion. In order to minimise the risk of harm to participants,
the clinicians with responsibility for the participants will
be instructed to consider the consequence of taking each
blood sample on a case-per-case basis and will not take a
blood sample if this is considered to be detrimental to the
participant. The clinician will be asked to sign the case re-
port (CRF) form to indicate they agree to each blood sam-
ple being taken.
Primary outcomes
The primary outcome is clinical concern about bleeding.
This outcome will be determined for the following time
intervals:
Interval A: The period between sample 1 and sample 2
Interval B: The period between sample 2 and chest
drain insertion.
Interval C: The first 12 h after chest drain insertion.
Clinical concern about bleeding is defined as:
1. High blood loss. Chest drain volume of either >5 ml/
Kg/hr in any 1 h interval or >3 ml/Kg/hr for 3
consecutive hours (Hazinski guidelines [7]) in
interval C.
OR
2. Any non-routine pro-haemostatic treatment given in
response to bleeding by the clinical team. This is
defined as any of the following: protamine given
after initial heparin reversal; fresh frozen plasma
(FFP); cryoprecipitate; platelet concentrates; any
anti-fibrinolytic drug; activated recombinant factor
VII (rFVIIa); fibrin sealant or fibrinogen concentrate.
The composite endpoint is necessary because of two
important constraints:
a) Blood loss is readily quantified after chest drain
insertion by measuring drain volume. However, in
intervals A and B (before chest drain insertion),
measurement of blood loss is not feasible.
b) Non-routine pro-haemostatic therapies are usually
given soon after the start of abnormal bleeding and,
if effective, prevent further bleeding. Measuring only
‘high blood loss’ would result in the primary endpoint
of excessive bleeding not being identified in these
instances.
There are two other circumstances in which clinicians
administer pro-haemostatic therapies during or after car-
diac surgery in children:
1. As part of our standard institutional protocols for all
children in the study population. These are termed
‘routine’ pro-haemostatic therapies and include
interventions such as cryoprecipitate infusion and the
administration of protamine to reverse the effects of
heparin at the end of surgery.
2. In response to a perceived risk of excessive bleeding
but before excessive bleeding starts. These are
termed ‘non-routine prophylactic’ pro-haemostatic
therapies and are usually given during interval B.
Clinicians will be asked to classify all pro-haemostatic
treatments in the study intervals A-C into one of three
categories i) ‘routine’, ii) ‘non-routine in response to
bleeding’; or ‘non-routine prophylactic’ on the study
CRFs. The ‘routine’ and ‘non-routine prophylactic’ pro-
haemostatic treatments will not be considered part of
the primary outcome.
In some children, blood from the CPB circuit (pump
blood) is re-infused during interval B and C requiring
additional protamine to be administered to reverse the
heparin contained in this blood. We have considered this
protamine dose to be part of the ‘routine’ management.
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Re-infusion of pump blood will be recorded on the CRF
but the additional protamine will not be classified as
part of the primary clinical outcome.
Secondary outcomes
Secondary clinical outcomes will be collected for all in-
tervals as follows:
a) Red cell transfusion expressed as any vs. none and
total red cell transfusion volume.
b) FFP, platelet concentrate and cryoprecipitate
transfusion expressed as any vs. none and total
volume of each blood component.
c) Non-blood component pro-haemostatic treatments
(extra protamine, rFVIIa, any antifibrinolytic drug,
fibrin sealant or fibrinogen concentrate) expressed as
total dose per Kg body weight of each agent.
d) Time from cessation of CPB to chest closure.
e) Post-operative complications or death.
Laboratory testing
Each blood sample will undergo parallel testing by:
1. Thromboelastometry (ROTEM, Tem Innovations
GmbH). Four different tests will be performed on
this platform (INTEM, EXTEM, FIBTEM and
HEPTEM tests using manufacturer's standard
reagents). Each test will yield eight parameters; i)
clot time (CT), ii) clot formation time (CFT), iii)
alpha angle, iv) maximum clot firmness (MCF),
v-vii) amplitude at 10, 20 and 30 min after CT and
viii) lysis index at 30 min after CT.
2. Reference laboratory tests. These tests will provide
10 measurements on each sample;
a) Prothrombin time and activated partial
thromboplastin time
b) Fibrinogen activity (Clauss assay)
c) Anti-Xa assay (heparin activity)
d) Endogenous thrombin potential ((ETP); thrombin
generation assay in plasma)
e) Platelet count
f ) Platelet function testing by whole blood electrical
impedance aggregometry (Multiplate, Roche
Diagnostics) with the Adenosine diphosphate
(ADP-test), Thrombin Receptor Activating Peptide
(TRAP-test) and Collagen (COLL-test) standard
manufacturer's reagents. The platelet function test
results will be expressed as area under curve, lag
time and amplitude.
Sample size calculation
The study size is 200 participants with blood samples
taken. In estimating the power of the study and preci-
sion of the estimates, we have assumed that the rate of
the primary outcome is 50 % in this population. Add-
itionally, we have considered two alternative estimates of
prevalence of blood clotting abnormalities (30 % and
5 %) in the study population:
Objective 1 (describing the prevalence of different
blood clotting abnormalities in the population): a sample
size of 200 participants will allow a prevalence of 30 %
to be estimated with a 95 % confidence interval of +/−
7 % (23.7 %, 36.9 %) and a prevalence of 5 % to be esti-
mated with a 95 % confidence interval of +/− 4 % (2.4 %,
9.0 %).
Objective 2 (estimating the extent to which TEM and
reference laboratory test results predict clinical concern
about bleeding): the power to estimate a relative risk of
a given magnitude is dependent on the prevalence of the
blood clotting abnormalities and increases with increasing
prevalence. The study will have a minimum of 77 % power
to estimate a relative risk of 1.5, given a rate of blood clot-
ting abnormalities of >30 % in the population and >80 %
power to estimate a relative risk of 2, given a rate of blood
clotting abnormalities of between 4 % and 5 %.
Objective 3 (estimating diagnostic accuracy of TEM
test results vs. reference test results): a sample size of
200 participants will allow the sensitivity and specificity
of each TEM test result to identify defined blood clotting
abnormalities with a prevalence of 30 % to be estimated
with a 95 % confidence interval of +/− 10 % (79.5 %,
96.2 %) for a sensitivity of 90 % increasing to +/−13 %
(46.5 %, 72.4 %) for a sensitivity of 60 %. The specificity
will be estimated with a 95 % confidence interval of +/−6 %
(83.8 %, 94.4 %) for a specificity of 90 % increasing to
+/−9 % (51.4 %, 68.2 %) for a specificity of 60 %. For a
prevalence of 5 %, the 95 % confidence intervals are +/−
35 % (55.5 %, 100 %) for a sensitivity of 90 % and +/−35 %
(26.4 %, 87.8 %) for a sensitivity of 60 %. The corresponding
figures for specificity are +/− 5 % (84.8 %, 93.9 %) for 90 %
specificity and +/− 7 % (52.7 %, 67.0 %) for 60 % specificity.
Study methods
Participants will undergo standard pre-operative, anaes-
thetic, surgical and post-operative care according to
existing institutional protocols. Decisions about the pre-
vention or treatment of excessive bleeding during or
after surgery will be guided by clinician judgement and
routine laboratory investigations (such as measurement
of heparin level) in accordance with our routine institu-
tional practice. These decisions will not be influenced by
study participation although clinicians will be asked to
record the indication for each pro-haemostatic treat-
ment during intervals A, B and C, as described above.
Blood samples will be taken from existing vascular lines
that are inserted as part of standard clinical care without
the need for additional venepunctures.
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In order to enable laboratory quality control and assay
validation purposes, blood samples not used in the initial
analyses will be stored at −80 °C for the duration of the
study. Specimens that are left over upon completion of the
study have the potential of being used for future research
relevant to cardiac surgery. Therefore, participants or their
parent/guardian are asked to give their permission for
samples to be retained after the end of the study for use in
other ethically approved research. The samples of partici-
pants who do not consent to this option will be destroyed
at the end of this study in accordance with the Human
Tissue Authority’s Code of Practice. The responsibility for
custodianship of samples retained beyond the end of this
study will lie with the Chief investigator.
Data collection will include the following elements:
(a) A log of all children having cardiac surgery
(b) A log of patients assessed against the eligibility
criteria and, if ineligible, reasons for ineligibility.
(c) A log of potential participants or parents/guardians
approached for the study (including the date when
they are given the Patient Information Leaflet).
(d) Consent and baseline information, including
demographic characteristics, clinical history, planned
procedure.
(e) Data characterising the participant’s hospital stay
(i) Operative details




(f ) Blood clotting abnormality test results collected as
part of the study will be obtained from the ROTEM
device hard-drive, Multiplate device hard-drive, ETP
device hard-drive, and for other tests, from the
Bristol University Hospitals NHS Foundation Trust
(UHBristol) electronic laboratory database.
(g) Data describing red blood cell, platelet and fresh
frozen plasma transfusions will be obtained from the
UHBristol blood bank electronic laboratory
database.
(h) Data describing all other pro-haemostatic
treatments.
A large amount of data will be available from routine
sources such as medical records and intra/post-operative
care charts. Study data will be recorded on a study CRF
before transfer to a custom made electronic database held
on a secure server. Study-specific CRFs will be used as
required.
Statistical analyses
In order to address objective 1 (describing the preva-
lence of the different types of blood clotting abnormality
before and after cardiac surgery) the following analyses
will be undertaken:
a) The distributions of the measurements from each
reference laboratory test will be characterised
separately for the two sample time-points.
b) Principal component, latent class or similar analyses
will be selected depending on the nature of the
distributions and will be used to define and describe
blood clotting abnormalities on the basis of the
reference laboratory test results.
c) The proportions of participants with different blood
clotting abnormalities based on the classification
determined in b) and with no blood clotting
abnormality will be described with 95 % confidence
intervals.
Logistic regression models will be fitted to estimate ex-
tent to which the individual results of the TEM and ref-
erence laboratory test results at each time point predict
clinical concern about bleeding (objective 2a). Receiver
operator characteristic (ROC) analyses will be performed
to identify optimal cut-off criteria for predicting clinical
concern about bleeding using separate analyses for each
category of blood clotting abnormalities. The most
prevalent clusters of abnormal reference laboratory test
results (identified in objective 1) will be represented as
semantic diagnostic terms representing different possible
blood clotting abnormalities (e.g. increased APTT and
increased anti-Xa heparin activity, but normal other ref-
erence laboratory tests indicates "residual heparin") and
associations between these terms and clinical concern
about bleeding will be investigated using logistic regres-
sion models (objective 2b).
We will estimate the diagnostic accuracy of TEM test
results for the different types of blood clotting abnor-
mality defined by the results of the reference laboratory
tests (objective 3) by calculating the sensitivity and spe-
cificity, likelihood ratios and positive and negative pre-
dictive values for different estimates of the prevalence of
blood clotting abnormality.
The agreement between the recommended treatments
resulting from the reference tests and the TEM test results
will be assessed using Kappa statistics (objective 4). The
proportion of participants correctly identified by diagnos-
tic models using either TEM or reference test results will
be subject to ‘optimism’ bias. Ideally, this would be ad-
dressed by validating models on ‘new’ data that is not used
for developing the models (‘train-and-test’ validation).
Since the sample size available for this study is not large
enough to permit this, we will consider alternative
methods such as cross-validation and boot-strapping.
Analyses relating to objectives 1, 2 and 3 above may
additionally be stratified by age group. The primary
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analysis will take place when all data have been col-
lected, samples analysed and the database is locked. No
interim analysis is planned.
Discussion
Since the DECISION study was conceived, the National
Institute of Clinical Excellence (NICE) have issued guid-
ance about the implementation of TEM and other rapid
viscoelastometric tests in clinical practice, including car-
diac surgery [10]. The guidance states that TEM are rec-
ommended to help monitor blood clotting during and
after heart surgery by healthcare professionals who have
had appropriate training. The Committee recommended
further research comparing the clinical effectiveness of
the three alternative commercial viscoelastometric de-
vices (ROTEM, TEG and Sonoclot systems) in cardiac
surgery to determine which test parameters are most use-
ful for informing treatment of excessive bleeding caused
by blood clotting abnormalities. This guidance is based
on a systematic review that excluded paediatric studies,
[10, 7] highlighting that there is still an unmet need to
evaluate the clinical utility of TEM testing in children.
Trial status
The trial opened to recruitment in May 2013 and it is
planned that the recruitment will be completed by May
2015. Recruitment is currently ahead of target.
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